Fig. 4

Antitumor activity of SCR-6852 in xenograft models. a–b ER-positive cancer cell line MCF-7 was implanted in Balb/c nude mice with 17β-Estradiol to stimulate tumor growth. Animals were treated with SCR-6852 (0.3, 1, 3, or 10 mg/kg, respectively, daily, orally) or 250 mg/kg fulvestrant (subcutaneous injection once a week). Tumor volume was evaluated twice per week until the study endpoint. a Mean tumor volume ± SEM. b Percent change in tumor volumes from individual animals from the start of treatment to the end of treatment. c–d T47D subcutaneous xenograft model was also used. Tumor-bearing Balb/c nude mice received the vehicle, 250 mg/kg fulvestrant, or SCR-6852 0.3, 1, 3 mg/kg (QD) (n = 8/group). d Tumor growth inhibition for each treatment group relative to vehicle at end of treatment. The error bars represent the standard error of the mean (SEM). **** P < 0.0001 versus vehicle, ^#### P < 0.0001 versus Fulvestrant